Kelun-Biotech says SKB500 posts 42.7% response rate in first-in-human solid tumor study at ASCO 2026

• Sichuan Kelun-Biotech presented first-in-human study results for its B7-H3 antibody-drug conjugate SKB500 at ASCO 2026.
• Trial results showed tumor shrinkage across several advanced solid cancers, with the strongest activity highlighted in small cell lung cancer.
• Safety at the selected dose was described as manageable, with fewer severe treatment-related side effects than a higher-dose group.
• The readout supports continued clinical development across multiple tumor types, with small cell lung cancer positioned as a lead opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606022000PR_NEWS_USPR_____CN73535) on June 03, 2026, and is solely responsible for the information contained therein.